Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges.
Auteurs : Wang X, Collet L, Rediti M, Debien V, De Caluwé A, Venet D, Romano E, Rothé F, Sotiriou C, Buisseret L Année : 2023 Journal : J Clin Med
Timing evolution of lobular breast cancer through phylogenetic analysis.
Auteurs : Fimereli D, Venet D, Rediti M, Boeckx B, Maetens M, Majjaj S, Rouas G, Marchio C, Bertucci F, Mariani O, Capra M, Bonizzi G, Contaldo F, Galant C, Van den Eynden G, Salgado R, Biganzoli E, Vincent-Salomon A, Pruneri G, Larsimont D, Lambrechts D, Desmedt C, Brown DN, Rothé F, Sotiriou C Année : 2022 Journal : EBioMedicine
Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D).
Auteurs : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart M Année : 2022 Journal : Breast Cancer Res Treat
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.
Auteurs : Chang CA, Jen J, Jiang S, Sayad A, Mer AS, Brown KR, Nixon AML, Dhabaria A, Tang KH, Venet D, Sotiriou C, Deng J, Wong KK, Adams S, Meyn P, Heguy A, Skok JA, Tsirigos A, Ueberheide B, Moffat J, Singh A, Haibe-Kains B, Khodadadi-Jamayran A, Neel BG Année : 2022 Journal : Cancer Discov
Incorporation of TILs in daily breast cancer care: how much evidence can we bear?
Auteurs : Lænkholm AV, Callagy G, Balancin M, Bartlett JMS, Sotiriou C, Marchio C, Kok M, Dos Anjos CH, Salgado R Année : 2022 Journal : Virchows Arch